Linked Life Data

20674826

Source:http://linkedlifedata.com/resource/pubmed/id/20674826

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-8-2
pubmed:databankReference
pubmed:abstractText
C1 esterase inhibitor (C1-INH) replacement is recommended as a first-line therapy for acute edema attacks in hereditary angioedema (HAE). Only limited pharmacokinetic analyses of the administered C1-INH in plasma are available.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1081-1206
pubmed:author
pubmed:copyrightInfo
Copyright 2010 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
pubmed:issnType
Print
pubmed:volume
105
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
149-54
pubmed:dateRevised
2011-1-11
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks.
pubmed:affiliation
Division of Immunology/Allergy, Department of Internal Medicine, University of Cincinnati Medical Center and Bernstein Clinical Research Center, Cincinnati, Ohio 45267-0563, USA. bernstja@ucmail.uc.edu
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Clinical Trial, Phase III, Research Support, N.I.H., Extramural